Interleukin-6 (IL-6) Level as an Indikator of Progresivity Rheumatoid Arthritis (RA) Disease

Putu Oky Ari Tania, Dorta Simamora, Wahyuni Dyah Parmasari, Febtarini Rahmawati

Abstract


Rheumatoid Arthritis (RA) is autoimmune disease that attacks joints and synovial tissues. Rheumatoid Arthritis is characterized by inflammation that involves production of cytokines such as Interleukin 6 (IL-6). Increasing of interleukin 6 has correlation with activity and progressivity of the disease. This research was designed to know whether IL- 6 could be used as indicator progressivity of RA. The method that used for measuring IL-6 level is ELISA (Enzyme Linked Immunosorbent Assay), using the principle antigen-antibody binding. In early stage there were 9 persons (S01, S02, S03, S04, S07, S08, S09, S10 and S14) with of IL-6 level (mean : 3.640 pg/mL), intermediate stage there were 3 persons (S06, S13 and S15) with IL-6 level (mean : 12.453 pg/mL), late stage : 3 persons (S05, S11 and S12) with IL-6 level (mean : 59.349 pg/mL).


Keywords


Rheumatoid Arthritis, Disease Progressivity, Interleukin 6 (IL-6)

Full Text:

PDF

References


Hashizume, M. and M. Mihara, The Roles of Interleukin-6 in the Pathogenesis of Rheumatoid Arthritis, Arthritis, 2011.

Patel, AM. And LW. Moreland, Interleukin-6 inhibition for treatment of rheumatoid arthritis: A review of tocilizumab therapy, Drug Design, Development and Therapy. 2010; 4 : 263–278.

Dewing, KA.,Stephen M. Setter, and Barbara A. Slusher, Osteoarthritis and Rheumatoid Arthritis 2012: Pathophysiology, Diagnosis, and Treatment, Nurse Practitioner Healthcare Foundation, 2012.

McInnes, IB., and G. Schett, The Pathogenesis of Rheumatoid Arthritis, The New England Journal of Medicine, 2011, 365;23.

Grover, HS, N. Gaba, A. Gupta, CN. Marya, Rheumatoid arthritis: a review and dental care considerations, Nepal Med Coll J, 2011; 13(2): 74-76.

Holt, K., A Review of Pathophysiology and Medicinal Treatment Options of Rheumatoid Arthritis, 2011.

Wellby, ML., Kennedy JA., True BS., Barreau P., Serum interleukin-6 and thyroid hormones in rheumatoid arthritis. Metabolism. 2001; 50(4):463-7.

Przybysz, M., K. Borysewicz , J. Szechinski and I. Katnik-Prastowska, Synovial fibronectin fragmentation and domain expressions in relation to rheumatoid arthritis progression, Rheumatology. 2007; 46:1071–1075.

Robak, A. Gladalska, H. Stepie´n and E. Robak. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis, Mediators of Inflammation, 1998; 7: 347–353.

Naka, Tetsuji, N. Nishimoto and T.Kishimoto, The paradigm of IL-6: from basic science to medicine, Arthritis Res, 2002, 4 (suppl 3): S233-S242.

Chung, Soo-Jin, Yong-Jin Kwon, Min-Chan Park, Yong-Beom Park, and Soo-Kon Lee,. The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patient, Yonsei Med J . 2011; 52(1):113-120.

Alvarez, JLP., Interleukin 6 in the Physiopathology of Rheumatoid Arthritis, Reumatol Clin. 2009; 5(1):34-39.

Ardvidson, NG., Disease Activity in Rheumatoid Arthritis, Doctoral thesis at Uppsala University 2003 from the Department of Medical Sciences. 2003.




DOI: http://dx.doi.org/10.30742/jikw.v3i1.44

Refbacks

  • There are currently no refbacks.


Copyright (c) 2014 Putu Oky Ari Tania, Dorta Simamora, Wahyuni Dyah Parmasari, Febtarini Rahmawati

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Jurnal Ilmiah Kedokteran Wijaya Kusuma is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License